Creoscience Joins KDCA's Marburg Fever Vaccine Project, Accelerating Next-Generation Pandemic Response

Creoscience is expanding its high-risk infectious disease response platform by participating in the next-generation Marburg fever vaccine development project led by the Korea Disease Control and Prevention Agency (KDCA).

On June 2, Creoscience announced that it will join as a joint research institution in the KDCA's project titled "Development of Marburg Fever Vaccine Candidates and Evaluation Methods for Next Pandemic Response." This project is supported by the KDCA and led by the International Vaccine Institute (IVI) as the principal research institution, with Creoscience and Cellid participating as joint research partners.

The goal of this project is to establish a rapid domestic response system to infectious diseases by securing Marburg fever vaccine candidates and building an immunogenicity evaluation system.

The Marburg virus is a filovirus pathogen that causes hemorrhagic fever symptoms similar to those of the Ebola virus. Infection can result in high fever, bleeding, and multiple organ damage, and in some outbreaks, fatality rates as high as 90% have been reported.

As of today, there is no commercialized Marburg fever vaccine available. The World Health Organization (WHO) has designated the Marburg virus as a priority pathogen for development under its R&D Blueprint, while the Coalition for Epidemic Preparedness Innovations (CEPI) has also included it as a key pathogen in its next-generation pandemic response strategy, the "100 Days Mission," reflecting the continued global need for vaccine development.

In this research project, the International Vaccine Institute will be responsible for antigen design using artificial intelligence (AI)-based structural prediction technology, development of recombinant protein-based candidates, and immunogenicity evaluation. Creoscience will conduct the production and characterization of Marburg fever vaccine candidates using a recombinant attenuated VSV platform.

The VSV-based vaccine platform is considered a next-generation vaccine technology that offers increased safety by reducing cytotoxicity through attenuation, while also enabling strong immune responses and rapid vaccine development. As a result, its potential application in infectious disease response is receiving significant attention.

A Creoscience representative stated, "It is crucial to take a proactive approach to high-risk infectious diseases such as Marburg fever, given their pandemic potential," adding, "We are developing preventive vaccines for various infectious diseases, including dengue virus, severe fever with thrombocytopenia syndrome virus (SFTSV), hantavirus, and Middle East respiratory syndrome coronavirus (MERS-CoV), using the recombinant attenuated VSV platform."

The representative further added, "By participating in this Marburg fever vaccine project, we will further expand our high-risk pathogen response platform technologies and strengthen our vaccine development capabilities, contributing to the establishment of a national infectious disease response system."

Through its participation in the Marburg fever vaccine development project, Creoscience is accelerating the expansion of next-generation pandemic response platform technologies and strengthening its capabilities in developing vaccines for high-risk infectious diseases.

This content was produced with the assistance of AI translation services.